Literature DB >> 12505691

In vivo imaging of the brain cannabinoid receptor.

Andrew N Gifford1, Alexandros Makriyannis, Nora D Volkow, S John Gatley.   

Abstract

The CB1 cannabinoid receptor is expressed in the brain at levels sufficient to serve as potential target for in vivo imaging using positron emission tomography (PET) or single photon emission computed tomography methodology. To date, the most promising radioligands for the in vivo imaging of this receptor have structures based on that of the cannabinoid antagonist, SR141716A. Rodent data obtained using these in vivo radiotracers has demonstrated that both the behavioral and neurochemical effects of cannabinoids occur at very low levels of receptor occupancy. More recently, an agonist radiotracer based on the structure of aminoalkylindole cannabinoids has also been examined for in vivo labeling of CB1 receptors. Although rodent studies have indicated that in vivo imaging of CB1 receptors is feasible, at the present time this receptor has still to be successful imaged in a human PET study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12505691     DOI: 10.1016/s0009-3084(02)00148-2

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  9 in total

Review 1.  Weaving single photon imaging into new drug development.

Authors:  P David Mozley
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

Review 2.  Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Authors:  Guy A Cabral; LaToya Griffin-Thomas
Journal:  Expert Rev Mol Med       Date:  2009-01-20       Impact factor: 5.600

Review 3.  Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use.

Authors:  Noble George; Emily G Gean; Ayon Nandi; Boris Frolov; Eram Zaidi; Ho Lee; James R Brašić; Dean F Wong
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

4.  Evaluation of cannabinoid type 1 receptor expression in the rat brain using [¹⁸F]MK-9470 microPET.

Authors:  I Miederer; S Maus; I Zwiener; G Podoprygorina; D Meshcheryakov; B Lutz; M Schreckenberger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-09       Impact factor: 9.236

5.  [¹²⁵I]SD-7015 reveals fine modalities of CB₁ cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease.

Authors:  Szabolcs Farkas; Katalin Nagy; Miklós Palkovits; Gábor G Kovács; Zhisheng Jia; Sean Donohue; Vic Pike; Christer Halldin; Domokos Máthé; Tibor Harkany; Balázs Gulyás; László Csiba
Journal:  Neurochem Int       Date:  2011-12-28       Impact factor: 3.921

6.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

7.  PET imaging studies in rhesus monkey with the cannabinoid-1 (CB1) receptor ligand [11C]CB-119.

Authors:  Terence G Hamill; Linus S Lin; William Hagmann; Ping Liu; James Jewell; Sandra Sanabria; WaiSi Eng; Christine Ryan; Tung M Fong; Brett Connolly; Amy Vanko; Richard Hargreaves; Mark T Goulet; H Donald Burns
Journal:  Mol Imaging Biol       Date:  2009-01-07       Impact factor: 3.488

8.  Cannabinoids for the treatment of schizophrenia? A balanced neurochemical framework for both adverse and therapeutic effects of cannabis use.

Authors:  Carissa M Coulston; Michael Perdices; Antony F Henderson; Gin S Malhi
Journal:  Schizophr Res Treatment       Date:  2010-07-27

Review 9.  Gliosis and Neurodegenerative Diseases: The Role of PET and MR Imaging.

Authors:  Carlo Cavaliere; Liberatore Tramontano; Dario Fiorenza; Vincenzo Alfano; Marco Aiello; Marco Salvatore
Journal:  Front Cell Neurosci       Date:  2020-04-02       Impact factor: 5.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.